Dr. Kishorkumar A. Desai, M.D.
Rheumatology (Rheumatology Physician)
1830 High St Ste A
Hopkinsville, KY 42240
Who else practices at this address →
Christian County is a federal mental health shortage area. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 32
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 752
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Rheumatology Physician primary
KY license 38463 · TN license 38325
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Owensboro Health Regional Hospital Owensboro, KY
- Vanderbilt Clarksville Hospital Clarksville, TN
- Baptist Health Deaconess Madisonville Madisonville, KY
- Jennie Stuart Medical Center Hopkinsville, KY
- Trigg County Hospital Cadiz, KY
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 752
- Services billed
- 271,911
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 229,800 | 68 |
| Injection, denosumab, 1 mg | 6,660 | 68 |
| Established patient office or other outpatient visit, 20-29 minutes | 2,195 | 716 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 1,410 | 131 |
| Injection of drug or substance under skin or into muscle | 1,324 | 147 |
| Established patient office or other outpatient visit, 30-39 minutes | 314 | 181 |
| Aspiration and/or injection of fluid from large joint | 166 | 94 |
| New patient office or other outpatient visit, 45-59 minutes | 125 | 125 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 99 | 13 |
| Insertion of needle into vein for collection of blood sample | 25 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 4 payments worth $89.98 in total to this clinician.
| AbbVie Inc. | $63.05 |
|---|---|
| Sandoz Inc. | $26.93 |
| Food and Beverage | $89.98 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 10 industry-funded studies in 2025, from 5 companies. The companies reported $199,079 in research payments for these studies, mostly to the institutions running them.
- A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)
E.r. Squibb & Sons, L.l.c. - A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Nave to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previo…
E.r. Squibb & Sons, L.l.c. - A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus
UCB SA · Enrolling by invitation · NCT04976322 - A Study of Baricitinib in Participants With Rheumatoid Arthritis
Eli Lilly and Company · Completed · NCT04086745 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus
AbbVie Inc. · Active, not recruiting · NCT05843643 - M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE)
AbbVie Inc. - M23-700 - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH)
AbbVie Inc. - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis
AbbVie Inc. · Completed · NCT05814627 - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH)
AbbVie Inc. - A Randomized, Parallel Group, Double Blind, Placebo Controlled Multicenter Phase III Trial to Investigate the Efficacy and Safety of Secukinumab 300 mg Administered Subcutaneously Versus Placebo, in Combination With G…
Novartis Pharmaceuticals Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.